Correlation Between Spyre Therapeutics and GP Act
Can any of the company-specific risk be diversified away by investing in both Spyre Therapeutics and GP Act at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Spyre Therapeutics and GP Act into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Spyre Therapeutics and GP Act III Acquisition, you can compare the effects of market volatilities on Spyre Therapeutics and GP Act and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Spyre Therapeutics with a short position of GP Act. Check out your portfolio center. Please also check ongoing floating volatility patterns of Spyre Therapeutics and GP Act.
Diversification Opportunities for Spyre Therapeutics and GP Act
0.08 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Spyre and GPAT is 0.08. Overlapping area represents the amount of risk that can be diversified away by holding Spyre Therapeutics and GP Act III Acquisition in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on GP Act III and Spyre Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Spyre Therapeutics are associated (or correlated) with GP Act. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of GP Act III has no effect on the direction of Spyre Therapeutics i.e., Spyre Therapeutics and GP Act go up and down completely randomly.
Pair Corralation between Spyre Therapeutics and GP Act
Given the investment horizon of 90 days Spyre Therapeutics is expected to under-perform the GP Act. In addition to that, Spyre Therapeutics is 43.33 times more volatile than GP Act III Acquisition. It trades about -0.24 of its total potential returns per unit of risk. GP Act III Acquisition is currently generating about 0.36 per unit of volatility. If you would invest 1,007 in GP Act III Acquisition on September 5, 2024 and sell it today you would earn a total of 7.00 from holding GP Act III Acquisition or generate 0.7% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 95.45% |
| Values | Daily Returns |
Spyre Therapeutics vs. GP Act III Acquisition
Performance |
| Timeline |
| Spyre Therapeutics |
| GP Act III |
Spyre Therapeutics and GP Act Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Spyre Therapeutics and GP Act
The main advantage of trading using opposite Spyre Therapeutics and GP Act positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Spyre Therapeutics position performs unexpectedly, GP Act can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GP Act will offset losses from the drop in GP Act's long position.| Spyre Therapeutics vs. Western Union Co | Spyre Therapeutics vs. Freedom Bank of | Spyre Therapeutics vs. Univest Pennsylvania | Spyre Therapeutics vs. NH Foods Ltd |
| GP Act vs. Tscan Therapeutics | GP Act vs. CECO Environmental Corp | GP Act vs. Spyre Therapeutics | GP Act vs. Kaiser Aluminum |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |